Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
OVERLAND PARK, Kan. - SelectQuote, Inc. (NYSE:SLQT), a healthcare and insurance services company with a market capitalization of $383 million and strong revenue growth of 20% over the last twelve months, announced Thursday the expanded launch of a concierge-like service aimed at improving medication adherence for Medicare beneficiaries with multiple chronic conditions. According to InvestingPro analysis, the company maintains healthy liquidity with a current ratio of 1.86, indicating strong operational capability for new service launches.
The company’s SelectRx pharmacy recently trialed the approach with a regional health plan, achieving over 90% adherence rates and strengthening HEDIS Star ratings across triple-weighted measures for cholesterol, diabetes and hypertension. For investors tracking healthcare innovation, InvestingPro offers comprehensive analysis of 1,400+ healthcare companies, including detailed metrics and expert insights on market opportunities in the sector.
SelectQuote plans to expand the program to additional payers this year before rolling it out across its SelectRx pharmacy platform in 2026.
The service proactively identifies high and medium-risk patients with complex medication regimens who have a higher likelihood of adherence gaps. When barriers to adherence are identified, cases can be escalated to the company’s clinical pharmacist team for specialized intervention.
"Our SelectRx pharmacy offering already dramatically improves medication adherence and other health measures through timely, convenient delivery and easy-to-use packaging," said Bob Grant, President of SelectQuote.
The company also plans to launch a complementary program for lower-risk members to support continued medication adherence.
Medication non-adherence is a significant challenge in healthcare that can lead to preventable hospitalizations, adverse drug interactions, and increased costs for the Medicare system.
SelectQuote, founded in 1985, operates an ecosystem offering services across insurance, Medicare, pharmacy, and value-based care. The company went public in 2020 and trades on the New York Stock Exchange. InvestingPro analysis indicates the stock is currently undervalued, with analysts predicting profitability this year despite recent market challenges. Additional ProTips and detailed financial metrics are available through InvestingPro’s comprehensive research platform.
The information in this article is based on a company press release statement.
In other recent news, SelectQuote reported its Q3 Fiscal 2025 earnings, revealing an earnings per share (EPS) of $0.03, which fell short of the forecasted $0.04. Despite this minor miss, the company’s revenue grew by 8% year-over-year, reaching $408.2 million, driven largely by the SelectRx segment. The SelectRx membership saw a 41% increase, contributing significantly to the company’s revenue growth. However, the earnings miss has raised concerns among investors about the company’s future profitability. In another development, SelectQuote announced the passing of its Vice Chairman, Tom Grant, who was instrumental in the company’s strategic development over the past 15 years. The company’s leadership transition appears stable, with Grant’s sons continuing in their executive roles. Furthermore, SelectQuote has maintained its full-year revenue and adjusted EBITDA ranges but adjusted its net income expectations, citing potential headwinds in its Healthcare Services segment due to facility ramp-up. Finally, the Department of Justice has filed a complaint against several participants in the Medicare Advantage system, including SelectQuote, which the company plans to contest vigorously.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.